← Back to Search

Device

rTMS for Cannabis Use Disorder

Phase 1 & 2

Recruiting

Led By Gregory Sahlem

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12-weeks

Awards & highlights

Study Summary

This trial is testing if a treatment called rTMS, combined with therapy, can help people reduce or quit using marijuana. Participants will receive rTMS to two different parts of the brain to see which is more effective.

Who is the study for?

This trial is for adults aged 18-60 with Cannabis Use Disorder who've used marijuana at least 20 days in the last month and want to cut down or quit. They must be able to consent, not be pregnant/breastfeeding, have no severe substance use disorders (except tobacco), stable medication regimens, no major mental health conditions requiring treatment, no cognitive impairments, and no contraindications to rTMS or MRI.Check my eligibility

What is being tested?

The study tests if repetitive transcranial magnetic stimulation (rTMS) can help reduce or stop marijuana use when combined with counseling. Participants will receive rTMS targeting one of two brain areas: the dorsolateral prefrontal cortex (DLPFC) or ventromedial prefrontal cortex (vmPFC), to determine which area might respond better.See study design

What are the potential side effects?

Possible side effects of rTMS include discomfort at the stimulation site, headache, lightheadedness, seizures are rare but possible risks associated with magnetic stimulation. Counseling therapy has minimal risk but may involve discussing uncomfortable topics.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12-weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12-weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12-weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Days per week of cannabis use

Secondary outcome measures

Weeks of abstinence from cannabis

Trial Design

2Treatment groups

Experimental Treatment

Group I: Ventromedial Prefrontal Cortex (vmPFC)Experimental Treatment1 Intervention

36 sessions of low frequency (1Hz) rTMS

Group II: Dorsolateral Prefrontal Cortex (DLPFC)Experimental Treatment1 Intervention

36 sessions of high frequency (10Hz) rTMS

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Repetitive Transcranial Magnetic Stimulation (rTMS)

2019

Completed Phase 2

~780

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,395 Previous Clinical Trials

17,341,328 Total Patients Enrolled

Gregory SahlemPrincipal InvestigatorStanford University

1 Previous Clinical Trials

3 Total Patients Enrolled

Media Library

rTMS (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05720312 — Phase 1 & 2

Cannabis Use Disorder Research Study Groups: Dorsolateral Prefrontal Cortex (DLPFC), Ventromedial Prefrontal Cortex (vmPFC)

Cannabis Use Disorder Clinical Trial 2023: rTMS Highlights & Side Effects. Trial Name: NCT05720312 — Phase 1 & 2

rTMS (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05720312 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial available to minors?

"The criteria for applicant selection for this trial necessitates that patients are between 18 and 60 years old. In total, 16 trials exist exclusively for minors while 43 studies target the elderly."

Answered by AI

Are there currently any vacancies in this clinical trial?

"Unfortunately, this medical trial is not taking on any more participants. The clinicaltrials.gov page shows that it was initially posted in March of 2023 and the last update to the study occurred at the end of January 2021. However, there are still 116 other studies with open recruitment slots available right now."

Answered by AI

Which patients are allowed to participate in this experiment?

"This medical trial seeks to enrol 30 individuals with cannabis use disorder between the ages of majority and seniority. To be eligible, applicants must satisfy DSM-5 criteria for a minimum moderate Cannabis Use Disorder, demonstrate an eagerness to diminish or halt usage, provide a positive UDS during enrollment visit (confirming habitual consumption), appear suitable for study participation as judged by investigators, grant informed consent due to their intellectual aptitude adequate enough to accurately complete assessment instruments, and fall within the specified age range."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Investigating Two rTMS Strategies to Treat Cannabis Use Disorder

Gregory Sahlem 2023. "Investigating Two rTMS Strategies to Treat Cannabis Use Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05720312.